Lion Biotechnologies (OTC Markets: LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). Their lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of Stage 4 metastatic melanoma. In Phase 2 clinical trials, patients treated with this product demonstrated objective response rates of 49%, significantly exceeding those associated with existing melanoma treatments. In addition to metastatic melanoma, their TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers. As they continue advancing their current clinical programs, they are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. SNNLive spoke with Dr. Manish Singh, Chairman & CEO of Lion Biotechnologies at the LD Micro Invitational 2013 in Bel Air, CA.
Dr. Singh begins by explaining that, “the best way to think of Lion Biotechnologies’ is of trying to fix the broken immune system that happens in the case of cancer patients. The cancer grows in patients who essentially have dysfunctional immune systems and by transplanting new sets of T-cells, you can potentially even cure these patients.” Dr. Singh goes on to say that “this technology was developed at the National Cancer Institute under Dr. Steven A. Rosenberg, where they are using this method to deal with patients with metastatic disease and an expected 3 to 4 months to live.” Dr. Singh indicates that, “if Lion Biotechnologies is able to change the immune system of these patients and be able to put back these T-Cells that recognize all the different types of tumor cells present, they could potentially cure the patient. Based on [their] data so far, 20% of patients with metastatic melanoma that would have typically died have been cured, with a cure defined as patients living over 5 years with no measurable disease whatsoever.” He concludes that Lion Biotechnologies’ “plan to do a Phase 3 clinical trial in this and hopefully based on that, this product gets approved for melanoma, and based on approval, plan to be in the market in 2018 or 2019.” For more information about Lion Biotechnologies, check out their website: http://lbio.com/.
© 2017 Stock News Now
Supported by Superior Web Solutions